Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Education & Training

  • Fellowship, Hematology & Oncology, 2001
    New York University School of Medicine
  • Residency, Pediatrics, 1999
    New York University School of Medicine
  • Internship, Pediatrics, 1997
    New York University School of Medicine
  • MD, 1993
    Christian-Albrechts Universitaet Zu Kiel

Board Certifications

  • American Board of Pediatrics/Hematology-Oncology

National Provider ID: 1043314784


Birte Wistinghausen, M.D., is a pediatric oncologist and member of the leukemia and lymphoma team. She treats children, adolescents and young adults with non-Hodgkin lymphoma (NHL), histiocytosis and leukemia. Her clinical research concentrates on non-Hodgkin lymphoma, specifically on the role of Epstein-Barr virus (EBV) in Post-Transplant Lymphoproliferative Syndrome (PTLD) and cellular therapy in EBV-positive PTLD as well as the biology and treatment of B-lymphoblastic lymphoma.

Dr. Wistinghausen's roles within the Children’s Oncology Group (COG) include serving as the principal co-investigator of a clinical study using EBV-specific T-cells in patients with post-transplant lymphoproliferative disease and being the responsible investigator for B-lymphoblastic lymphoma. She is also serving as vice-chair for education of the COG NHL committee.

Research & Publications

Meyer JA, Zhou D, Mason CC, et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatric Blood and Cancer. 2017;64(7).

Hayashi, RJ, Wistinghausen B, Shiramizu B. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Pizzo P, Poplack D, ed. Principles and Practice of Pediatric Oncology. 7th Ed. South Holland, Netherlands: Wolters Kluwer; 2016:24.

Llaurador G, McLaughlin L, Wistinghausen B. Management of post-transplant lymphoproliferative disorders. Curr Opin Pediatr. 2016;29(1):34-40.